New Trials to Target Antibiotics for Pneumonia and UTIs
Two comprehensive studies have demonstrated the effectiveness of algorithm-driven alerts in optimizing antibiotic selection for hospitalized patients with pneumonia...
New Insights on How Walgreens Clinical Trials Operate
In a conversation with Ramita Tandon, Walgreens’ Chief Clinical Trials Officer, we explore the company’s cutting-edge strategies to maximize...
Unveiling the Revolutionary ALECENSA: A Game-Changer for ALK+ Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the treatment of patients with ALK-positive non-small...
OPM Obtains €5.6 Million for DEMOCRITE Program’s Clinical Development
Oncodesign Precision Medicine (OPM) has received €5.6 million in funding for the DEMOCRITE project, aimed at demonstrating the efficacy...
Delve Bio Presents Study: mNGS in Neurological Infections
Delve Bio and researchers at the University of California, San Francisco collaborated to showcase the potential of metagenomic next-generation...
Artifa’s Allonk: Unprecedented Lupus Breakthrough
Artiva Biotherapeutics has begun a Phase 1 trial of its AlloNK (AB-101) cell therapy in combination with monoclonal antibodies...
Unpacking FDA’s Discussion Paper on AI in Clinical Trials
In a pioneering initiative, the Food and Drug Administration (FDA) has laid out a comprehensive discussion paper focusing on...
Precision Biosciences’ Programs Make a Stunning Return: Collaboration with Prevail Therapeutics Concludes
Precision BioSciences has regained control of three gene editing programs from Prevail Therapeutics, a subsidiary of Eli Lilly. The...
Medincell’s Partnership with AbbVie: Unlocking Next-Gen Injectable Therapies
Medincell has teamed up with AbbVie to develop and commercialize up to six innovative long-acting injectable (LAI) therapies. This...
Calidi Biotherapeutics IPO Raises $6.1 Million
Calidi Biotherapeutics, a biotechnology company focused on developing targeted immunotherapies, has priced its public offering for 15,197,500 shares of...